4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Insomnia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 185 ongoing clinical trials involving Insomnia
Of the 185 trials,65 trials are in Phase II
Furthermore, 38 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Insomnia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Insomnia, a Central Nervous System disorder. The largest number of ongoing clinical trials for Insomnia is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Insomnia -related drug trials.

Johnson & Johnson: The leading ongoing Insomnia related clinical trial sponsor

Johnson & Johnson is the top sponsor for Insomnia-related ongoing clinical trials.

Eisai Co Ltd, Idorsia Pharmaceutical Ltd, VA Office of Research and Development, and Massachusetts General Hospital are among other notable clinical trial sponsors involved in Insomnia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Insomnia

Suvorexant (Belsomra/ Silumbra), Eszopiclone (Lunesta) and Ramelteon (Rozerem) are among the key marketed drugs involving Insomnia.

Suvorexant (Belsomra/ Silumbra) is a dual orexin receptor antagonist. It functions via Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) Antagonist; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) Antagonist mechanism of action. Suvorexant is formulated as film-coated tablets and tablets for oral route of administration. Suvorexant was first approved in 2014 and is marketed in the US, Australia, Canada, Japan and New Zealand by several prominent pharma giants including Merck & Co Inc.

Eszopiclone (Lunesta) is a cyclopyrrolone, nonbenzodiazepine derivative, acts as a hypnotic agent. It functions via Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA(A) Receptor or GABR) Agonist mechanism of action. Eszopiclone is formulated as film-coated tablets for oral route of administration. Lunesta is indicated for the treatment of insomnia. Eszopiclone was first approved in 2004 and is marketed in the US, Canada and Japan by several prominent pharma giants including Sunovion Pharmaceuticals Inc.